Mircera® in Dialysis – a US Experience

When:  Jun 30, 2021 from 01:00 PM to 02:00 PM (ET)
Since December 2014, Mircera® (methoxy polyethylene glycol-epoetin beta) injection, for intravenous or subcutaneous use, has been available in the United States. Initially, available exclusively via FKC dialysis clinics, as of late 2017, Mircera® was introduced by other dialysis providers as well. Expanded use of Mircera® in recent years has allowed many US dialysis providers to gain valuable first-hand experience with this long-acting ESA, some of which has been described and shared in recent publications. Presenters will share general information, key findings, and published conclusions based on the Mircera® US experience.

Sponsored by